Numonafide

Drug Profile

Numonafide

Latest Information Update: 18 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwestern University
  • Developer Northwestern University; Panther Biotechnology
  • Class Antineoplastics; Isoquinolines; Naphthalimides; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Apr 2015 Numonafide licensed to Panther Biotechnology worldwide
  • 01 Apr 2015 Panther Biotechnology announces intention to submit IND to US FDA in 2015
  • 01 Apr 2015 Panther Biotechnology plans a phase I/II trial for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top